| Home  | About ScienceAsia  | Publication charge  | Advertise with us  | Subscription for printed version  | Contact us  
Editorial Board
Journal Policy
Instructions for Authors
Online submission
Author Login
Reviewer Login
Volume 48 Number 5
Volume 48 Number 4
Volume 48 Number 3
Volume 48 Number 2
Volume 48S Number 1
Volume 48 Number 1
Earlier issues
Volume 48 Number 4 Volume 48 Number 5

previous article next article

Research articles

ScienceAsia 48 (2022): 545-551 |doi: 10.2306/scienceasia1513-1874.2022.082


Isorhapontigenin improves the sensitivity of non-small cell lung cancer cells to gefitinib by inactivation of the SP1/EGFR pathway


Xingshu Wua, Zhixiang Sub, Xiaoping Rena,*

 
ABSTRACT:     Non-small cell lung cancer (NSCLC) remains one of the most common cancers in the world. The aim of this study was to explore the therapeutic potential of isorhapontigenin (ISO) to overcome gefitinib resistance in NSCLC cells. Cell viability was higher in gefitinib-resistance A549 (A549/R) cells than that in A549 cells in response to gefitinib. Combination of gefitinib and ISO enhanced the reduction in cell viability and cell colony number induced by gefitinib or ISO alone. The number of apoptotic cells was increased in gefitinib and ISO combination group compared with A549/R cells treated with gefitinib or ISO alone. Combination of gefitinib and ISO inhibited the repairment of DNA damage in A549/R cells and repressed the activation of SP1/EGFR signaling pathway. In summary, data of this study proved that ISO enhanced the sensitivity to gefitinib through inactivation of SP1/EGFR signaling pathway in gefitinib-resistant NSCLC cells.

Download PDF

9 Downloads 124 Views


a Respiratory Department II, Shaanxi Provincial People?s Hospital, Shaanxi 710068 China
b Third Branch of Medicine, Shaanxi Cancer Hospital, Shaanxi 710061 China

* Corresponding author, E-mail: renxiaoping10903@163.com

Received 2 Nov 2021, Accepted 18 Mar 2022